Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials - Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm

Journal of Immunological Methods

Volumn 424, Issue , 2015, Pages 43-52

  Vessillier, S ^a   Eastwood, D ^a   Fox, B ^a   Sathish, J ^b   Sethu, S ^b   Dougall, T ^a   Thorpe, S J ^a   Thorpe, R ^a   Stebbings, R ^a,b,c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c MEDIMMUNE   (United States)

Author keywords

Cytokine release assay; Group size; PBMC; TGN1412; Therapeutic mAb; Whole blood

Indexed keywords

ALEMTUZUMAB; DACLIZUMAB; FC GAMMA RECEPTOR I; GLYCOPHORIN A; IMMUNOGLOBULIN RECEPTOR; OKT 3; RITUXIMAB; TGN 1412; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYTOKINE; GLYCOPHORIN; GYPA PROTEIN, HUMAN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TGN-1412 MONOCLONAL ANTIBODY;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DRUG SAFETY; ERYTHROCYTE; FIRST IN HUMAN STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; PERIPHERAL BLOOD MONONUCLEAR CELL SOLID PHASE CYTOKINE RELEASE ASSAY; PRIORITY JOURNAL; WHOLE BLOOD CYTOKINE RELEASE ASSAY; BLOOD; DRUG EFFECTS; FLUOROIMMUNOASSAY; METABOLISM; MONONUCLEAR CELL; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CYTOKINES; ERYTHROCYTES; FLUOROIMMUNOASSAY; GLYCOPHORIN; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR;

EID: 84940460680     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2015.04.020     Document Type: Article

References (49)

1. Acuto O., Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 2003, 3:939.
2. Alegre M.-L., Collins A.M., Pulito V.L., Brosius R.A., Olson W.C., Zivin R.A., Knowles R., Thistlethwaite J.R., Jolliffe L.K., Bluestone J.A. Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J. Immunol. 1992, 148:3461.
3. Afonso G., Scotto M., Renand A., Arvastsson J., Vassilieff D., Cilio C.M., Mallone R. Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms. J. Immunol. Methods 2010, 359:28.
4. Agarwal A., Vieira C.A., Book B.K., Sidner R.A., Fineberg N.S., Pescovitz M.D. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am. J. Transplant. 2004, 4:1357.
5. Ascierto P.A., Simeone E., Sznol M., Fu Y.X., Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin. Oncol. 2010, 37:508.
6. Bailey L., Moreno L., Manigold T., Krasniqi S., Kropshofer H., Hinton H., Singer T., Suter L., Hansel T.T., Mitchell J.A. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J. Pharmacol. Toxicol. Methods 2013, 68:231.
7. Bartholomaeus P., Semmler L.Y., Bukur T., Boisguerin V., Römer P.S., Tabares P., Chuvpilo S., Tyrsin D.Y., Matskevich A., Hengel H., Castle J., Hünig T., Kalinke U. Cell contact-dependent priming and Fc interaction with CD32+ immune cells contribute to the TGN1412-triggered cytokine response. J. Immunol. 2014, 192:2091.
8. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012, 119:5640.
9. Calarota S.A., Baldanti F. Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin. Dev. Immunol. 2013, 2013:637649.
10. Chatenoud L., Ferran C., Legendre C., Thouard I., Merite S., Reuter A., Gevaert Y., Kreis H., Franchimont P., Bach J.F. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990, 49:697.
11. Chu J.W., Sharom F.J. Glycophorin A interacts with interleukin-2 and inhibits interleukin-2-dependent T-lymphocyte proliferation. Cell. Immunol. 1992, 145:223.
12. Dhir V., Fort M., Mahmood A., Higbee R., Warren W., Narayanan P., Wittman V. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies. J. Immunotoxicol. 2012, 9:34.
13. Eastwood D., Findlay L., Poole S., Bird C., Wadhwa M., Moore M., Burns C., Thorpe R., Stebbings R. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 2010, 161:512.
14. Eastwood D., Bird C., Dilger P., Hockley J., Findlay L., Poole S., Thorpe S.J., Wadhwa M., Thorpe R., Stebbings R. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Br. J. Clin. Pharmacol. 2013, 76:299.
15. European Medicines Agency Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. CHMP/SWP/28367/07 2007, (Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf (last accessed 20/3/2015)).
16. Finco D., Grimaldi C., Fort M., Kiessling A., Wolf B., Salcedo T., Faggioni R., Schneider A., Ibraghimov A., Scesney S., Serna D., Prell R., Stebbings R., Narayanan P.K. Cytokine release assays: current practices and future directions. Cytokine 2014, 66:143.
17. Findlay L., Sharp G., Fox B., Ball C., Robinson C.J., Bird C., Stebbings R., Eastwood D., Wadhwa M., Poole S., Thorpe R., Thorpe S.J. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture. Cytokine 2011, 55:141.
18. Geginat J., Sallusto F., Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naïve, central memory, and effector memory CD4+ T cells. J. Exp. Med. 2001, 194:1711.
19. Harari A., Zimmerli S.C., Pantaleo G. Cytomegalovirus (CMV)-specific cellular immune responses. Hum. Immunol. 2004, 65:500.
20. Hoffmeister B., Bunde T., Rudawsky I.M., Volk H.D., Kern F. Detection of antigen-specific T cells by cytokine flow cytometry: the use of whole blood may underestimate frequencies. Eur. J. Immunol. 2003, 33:3484.
21. Hu Y., Turner M.J., Shields J., Gale M.S., Hutto E., Roberts B.L., Siders W.M., Kaplan J.M. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology 2009, 128:260.
22. Hussain K., Hargreaves C.E., Roghanian A., Oldham R.J., Chan H.T., Mockridge C.I., Chowdhury F., Frendéus B., Harper K.S., Strefford J.C., Cragg M.S., Glennie M.J., Williams A.P., French R.R. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 2015, 125:102.
23. Jones J.D., Hamilton B.J., Skopelja S., Rigby W.F. Induction of interleukin-6 production by rituximab in human B cells. Arthritis Rheum. 2014, 66:2938.
24. Li F., Ravetch J.V. A general requirement for FcγRIIB co-engagement of agonistic anti-TNFR antibodies. Cell Cycle 2012, 11:3343.
25. Liao W., Lin J.X., Leonard W.L. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13.
26. Lim L.C., Koh L.P., Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J. Clin. Oncol. 1999, 17:1962.
27. Lühder F., Huang Y., Dennehy K.M., Guntermann C., Müller I., Winkler E., Kerkau T., Ikemizu S., Davis S.J., Hanke T., Hünig T. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 2003, 197:955.
28. McKenna K.C., Beatty K.M., Vicetti Miguel R., Bilonick R.A. Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T cell function. J. Immunol. Methods 2009, 341:68.
29. Moreau T., Coles A., Wing M., Isaacs J., Hale G., Waldmann H., Compston A. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996, 119:225.
30. Römer P.S., Berr S., Avota E., Na S.Y., Battaglia M., ten Berge I., Einsele H., Hünig T. Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412. Blood 2011, 118:6772.
31. Rudd C.E., Schneider H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat. Rev. Immunol. 2003, 3:544.
32. Sheridan J.P., Zhang Y., Riester K., Tang M.T., Efros L., Shi J., Harris J., Vexler V., Elkins J.S. Intermediate-affinity interleukin-2 receptor expression predicts CD56 (bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult. Scler. 2011, 17:1441.
33. Siders W.M., Shields J., Garron C., Hu Y., Boutin P., Shankara S., Weber W., Roberts B., Kaplan J.M. Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor models. Leuk. Lymphoma 2010, 51:1293.
34. Stebbings R., Findlay L., Edwards C., Eastwood D., Bird C., North D., Mistry Y., Dilger P., Liefooghe E., Cludts I., Fox B., Tarrant G., Robinson J., Meager T., Dolman C., Thorpe S.J., Bristow A., Wadhwa M., Thorpe R., Poole S. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J. Immunol. 2007, 179:3325.
35. Stebbings R., Eastwood D., Poole S., Thorpe R. After TGN1412: recent developments in cytokine release assays. J. Immunotoxicol. 2013, 10:75.
36. Thorpe S.J., Stebbings R., Findlay L., Eastwood D., Poole S., Thorpe R. How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013, 64:471.
37. Suthanthiran M., Fotino M., Riggio R.R., Cheigh J.S., Stenzel K.H. OKT3-associated adverse reactions: mechanistic basis and therapeutic options. Am. J. Kidney Dis. 1989, 14:39.
38. Suntharalingam G., Perry M.R., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018.
39. TeGenero A.G. TGN1412 Investigational Medicinal Product Dossier Available at, (last accessed 20/3/2015). http://www.circare.org/foia5/tgn1412dossier.pdf.
40. Van Berkel M.E.A.T., Oosterwegel M.A. CD28 and ICOS: similar or separate costimulators of T cells?. Immunol. Lett. 2006, 105:115.
41. Vidal J.M., Kawabata T.T., Thorpe R., Silva-Lima B., Cederbrant K., Poole S., Mueller-Berghaus J., Pallardy M., Van der Laan J.W. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 2010, 51:213.
42. Waibler Z., Sender L.Y., Merten C., Hartig R., Kliche S., Gunzer M., Reichardt P., Kalinke U., Schraven B. Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies. PLoS One 2008, 3:e1708.
43. Walker M.R., Makropoulos D.A., Achuthanandam R., Van Arsdell S., Bugelski P.J. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. Int. Immunopharmacol. 2011, 11:1697.
44. White A.L., Dou L., Chan H.T., Field V.L., Mockridge C.I., Moss K., Williams E.L., Booth S.G., French R.R., Potter E.A., Butts C., Al-Shamkhani A., Cragg M.S., Verbeek J.S., Johnson P.W., Glennie M.J., Beers S.A. Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. J. Immuno. 2014, 193:1828.
45. Wing M.G., Moreau T., Greenwood J., Smith R.M., Hale G., Isaacs J., Waldmann H., Lachmann P.J., Compston A. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 1996, 98:2819.
46. Winkler U., Jensen M., Manzke O., Schulz H., Diehl V., Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999, 94:2217.
47. Wolf B., Morgan H., Krieg J., Gani Z., Milicov A., Warncke M., Brennan F., Jones S., Sims J., Kiessling A. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 2012, 60:828.
48. Wolf B., Morgan H., Brennan F., Krieg J., Gani Z., Jones S., Kiessling A. Response to the letter to the editor by Susan Thorpe et al.: how predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013, 64:473.
49. Xiong F., Janko M., Walker M., Makropoulos D., Weinstock D., Kam M., Hrebien L. Analysis of cytokine release assay data using machine learning approaches. Int. Immunopharmacol. 2014, 22:465.